1. Lue JK, Amengual JE. Emerging EZH2 inhibitors and their application in lymphoma. Curr Hematol Malig Rep. 2018;13(5):369–82.
2. Histone. 2014. https://www.nature.com/scitable/definition/histones-57/. Accessed 12 Feb 2020.
3. Gulati N, Beguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59(7):1574–85.
4. Epizyme. Epizyme announces exercise of $50 million option with Royalty Pharma and highlights key 2020 initiatives to build long-term value [media release]. http://www.epizyme.com. Accessed 6 Jan 2020.
5. Epizyme. Epizyme reacquires global rights from Eisai for first-in-class EZH2 inhibitor EPZ-6438 [media release]. 13 Mar 2015. http://www.epizyme.com.